Medicollect mobility scooter lottery

Mobility Scooter

We have compiled a list with the most frequently asked questions on Medicollect’s Mobility Scooter Lottery. 

1) What can you win? There is only one prize in the competition and it is a Roma Valencia Travel Mobility Scooter.

2) Can the prize be exchanged for cash? No, the prize cannot be exchanged for cash.

3) Who pays for delivery of the scooter? Medicollect pays delivery costs for mailing addresses in mainland UK. The scooter will be shipped within 2-3 business days of prize notification. A delivery time of 5 business days can be expected for most of mainland UK.

4) Who is organizing this lottery? The company Medicollect is responsible for this lottery. You can read more about Medicollect at

5) Who can participate in the lottery? All citizens of the UK with a documented MS diagnosis can participate in the competition.

6) Can I enter more than once? Participants can enter the competition one time only.

7) What are the chances of winning? Medicollect will raffle of the mobility scooter when 1000 people diagnosed with MS have joined The British MS Research Panel. Therefore, there is 1/1000 chance of winning.

8) When will the winning lottery be drawn? Medicollect will draw the winner within 30 days of The British MS Research Panel reaching its goal of 1000 members.

9) Does everyone have an equal chance of winning? Yes, each member who has fit the requirement of having an MS diagnosis, living in the UK, with one entry in the draw, will have 1 chance of winning.  

10) Does it cost anything to participate? No, membership with The British MS Research Panel does not cost anything. All that is required to participate in the draw is that you, as a resident of the UK, register as a member of The British MS Research Panel and that you have been given a formal MS diagnosis.

JOIN The British MS Research Panel AND JOIN THE LOTTERY FOR 1 Roma Valencia Travel Mobility Scooter. CLICK this link to join survey 

The full legal description of the lottery is here:


SANOFI places double order in UK

Following the vendor qualification in July, SANOFI rushed to place not just one but two orders with Medicollect.

In line with Medicollect’s core competence, the company will assist SANOFI with recruiting people with diabetes for 2 clinical trials in UK.

Rene Ludwigs, CEO in Medicollect, is particular proud of these projects: “SANOFI is the worlds second largest producer of diabetes medicines.

So to have them requesting our services is a true seal of approval to us. We are of course proud that global pharmaceutical companies find our patient recruitment services is the best solution in the market”.

Want to know more?

Contact Rene Ludwigs (CEO)

SANOFI finalizes vendor qualification with Medicollect

Since 2014, Medicollect has been working with the worlds largest pharmaceutical companies, helping them recruit patients for their clinical trials.

As projects scale up, the time has come to focus on vendor qualifications. Until recently, both Novartis and MSD have completed these extensive qualification procedures and approved the Medicollect set-up.

SANOFI is the latest, scrutinizing all SOP’s submitted by Medicollect for vendor qualification, making it the third finalized procedure from a global pharmaceutical company.

As Rene Ludwigs, CEO of Medicollect, phrases it, “We are, of course, proud that global pharmaceutical companies are eager to enter into vendor partnerships with Medicollect.  We focus exclusively on solving the recruitment challenges faced by companies involved with clinical trials and our services put forth the best solution the market has to offer right now”.

Want to know more?

Contact Rene Ludwigs (CEO)

Medicollect provides user friendly software for patient recruitment

Medicollect is proud to present Enroller, a truly innovative IT project the company has been involved in since late 2015.

Enroller is a software solution developed specifically for presenting elevated security level patient data to hospital personnel in a user friendly way.

As a screening tool, Enroller captures all data gathered throughout the screening process, providing a total picture of the patient at a glance for Medicollect staff as well as hospital personnel. Enroller not only speeds up the process of screening patients for clinical trials, it also improves the quality of the screening and elevates the level of security with which patients’ sensitive information is treated.

The project is sponsored by the Innovation Fund Denmark, and has been developed in close partnership with the Danish diabetes community, The Life With Diabetes.

For introduction to Enroller, please contact CEO Rene Ludwigs.

Neurology added as a Medicollect core competence

Medicollect’s competences on recruiting people with diabetes for clinical trials have been in great demand.

 Based on clients’ requests Medicollect has decided to add Neurology as a core recruitment service. In UK Medicollect already has a client, Canbex Therapeutics, who is dedicated to treating spasticity in multiple sclerosis. 

The company CEO, Rene Ludwigs agrees that it is a bold move:

“It’s clearly a very ambitious strategy to expand that quickly, but we have set the pace high because our clients are happy with our services. We are looking forward to working on other MS projects as well as projects focusing on Alzheimer’s and Parkinson. “

So far, companies such as Novartis, GSK, and the international CRO, Pharm-Olam, have shown interest in using Medicollect’s recruitment services within neurology as well.

CRO Medpace initiates cooperation with Medicollect

After being approved as a supplier to some of the world’s largest pharma companies, Medicollect is proud of also having completed vendor qualification in one of the largest CROs, Medpace.

Medpace has operations in over 50 countries and holds a strong position in diabetes trials. Therefore Medicollect and Medpace match exceptionally well.

Medpace has already asked Medicollect to provide participants for a study on the treatment of diabetic foot ulcers in both the UK and Denmark. We expect a lot from the cooperation with Medpace “says Rene Ludwig, CEO of Medicollect.

Patient recruitment company for diabetes trials, Medicollect, increases investments and enters UK market.

Copenhagen, Denmark – Medicollect today announced its expansion into UK, increasing its acceptance footprint across the continent. The addition of the British network extends the company’s reach to 3, 4 million diabetes patients.

According to a report produced for the drug company Novartis clinical trials in the United Kingdom cost significantly more than in other European countries, in large because of poor rates of recruitment (source).

“This means that there is an increasing need for innovative and reliable solutions that address market needs,” says Torben Lind, COO at Medicollect. “Our investment in UK will secure that test patients for clinical diabetes trials in United Kingdom will be provided at the same fast, safe and reliable way that Medicollect has serviced the Scandinavian market.

Through collaborating with diabetes stakeholders in UK and Denmark, Medicollect is directly contributing to bringing medical innovation to patients faster and support United Kingdom’s transformation to once more being a strong center for clinical trials.

Want to know more?
Contact Torben Lind

Medicollect expands to UK

There has been great interest in participating in Medicollect’s diabetic panel in Denmark. Therefore Medicollect has decided to establish a panel in England.

In UK the panel will be called “My Life With Diabetes” and the goal is to reach 50,000 British members during 2016.

“It’s clearly a very ambitious goal, but we have set the goal high because our clients demand far more patients in England than in Denmark,” says director Henrik Vincentz.

So far, companies such as SANOFI, NOVO and GSK have shown interest in using Medicollect’s services in UK.

Medicollect gets new CEO

Medicollect was founded in 2012 by Henrik Vincentz and Torben Lind. Since then the company has grown its client base substantially, and the business has proved its sustainability.

In order to strengthen its international profile, the founders have decided to invite a new partner and CEO into the company, and the choice has fallen on Rene Vind Ludwigs, who with his experience in pharma and medical device industry brings strong skills and a comprehensive knowledge of customers’ business processes .

“We are absolutely convinced that we have made the right choice by inviting Rene Ludwig in as a partner”, says the founder, Henrik Vincentz.

Rene Ludwig comes from a position as CSO at Mission Pharma and before that he worked several years as General Manager at GN Resound and at Ambu.

Medicollect’s management now consists of CEO Rene Ludwig, COO Torben Lind and CCO Henrik Vincentz.